Trial ID or NCT#

NCT00928226

Status

not recruiting iconNOT RECRUITING

Purpose

The maximum tolerated dose of 3-session (ie, treatment) stereotactic radiosurgery (SRS) to treat brain metastases greater than 4.2 cm³ in size will be determined. This study investigates if increasing radiation dose improves outcome for patients without greater toxicity (side effects).

Official Title

A Phase I/II Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Scott G. Soltys, MD
Scott G. Soltys, MD
Radiation oncologist
Associate Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery at the Stanford University Medical Center
Steven D. Chang, MD
Steven D. Chang, MD
Neurosurgeon, Aneurysm neurosurgeon, Cerebrovascular neurosurgeon, Pituitary tumors neurosurgeon, Stereotactic neurosurgeon
Robert C. and Jeannette Powell Neurosciences Professor and, by courtesy, of Otolaryngology-Head and Neck Surgery and of Neurology
John R. Adler, MD
Iris C. Gibbs, MD, FACR, FASTRO
Iris C. Gibbs, MD, FACR, FASTRO
Radiation oncologist, Neuro-oncologist
Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery at the Stanford University Medical Center
Gordon Li, MD
Gordon Li, MD
Neurosurgeon
Associate Professor of Neurosurgery and, by courtesy, of Neurology and of Otolaryngology-Head and Neck Surgery at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Ccto-office@stanford.edu
(650) 498-7061